Cytek Biosciences, Inc. (NasdaqGS:CTKB) is looking for merger and acquisitions. Wenbin Jiang said, "And another area of our focus is we want to focus on our execution speed, our execution efficiency. And for any projects we develop, we want to make sure we spend our dollars smartly.

And lastly, we are going to continue to focus on finding opportunities for merger and acquisitions. Over the years, we acquired Tonbo, acquired our soaring flow cytometry business. We'll continue to look at -- look for opportunities to help expand our capability to find opportunities that match Cytek cell analysis capability, match our global presence, match our commercial efforts, commercial capabilities.

However, 1 of the areas of focus -- attention for any acquisition is we want to make sure whatever business we pick up, we will be able to make it profitable within the next following few quarters. That should be accretive to our profitability. This certainly -- it places a high bar these days for many available opportunities out there.

However, we are committed. This is what we are trying to achieve".